Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Kevin Costa
Icahn School of Medicine at Mount Sinai, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
NovoHeart
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Kevin Costa (the Principal Investigator in this study) is a scientific co-founder and equity holder in NovoHeart, a privately held company that is working to develop and engineer bio-artificial human heart prototypes using a combination of stem cell and tissue engineering approaches. Research being conducted in this study could potentially affect the value of NovoHeart.
Harnessing Paracrine Mechanisms of Stem Cell-mediated Cardiac Contractile Enhancement
PROJECT NARRATIVE To deepen our understanding of how injection of stem cells into the heart can enhance cardiac performance, we will combine state-of-the-art human cardiac tissue engineering technology with the latest advances in stem cell signaling biology to identify and isolate stem cell-secreted microvesicles, called exosomes, that can transport contractility-enhancing molecular cargo to cardiac cells. Success of this proposed research may lead to improved therapeutics that capture the benefits of injecting stem cells into the heart while circumventing the potential risks, helping improve treatment options for patients who suffer from heart failure.
Filed on April 19, 2017.
Tell us what you know about Kevin Costa's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Kevin Costa”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Kevin Costa | Icahn School of Medicine at Mount Sinai | Conflict of Interest | NovoHeart LTD | Value cannot be readily determined |
| Kevin Costa | Icahn School of Medicine at Mount Sinai | Conflict of Interest | NovoHeart | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.